These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2918046)

  • 21. Pharmacokinetic study of orally administered RU 486 in non-pregnant women.
    He CH; Shi YE; Ye ZH; Zhang GG; Jiang NX; Van Look PF; Fotherby K
    Contraception; 1989 Oct; 40(4):449-60. PubMed ID: 2582770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction of delta-5-androstene-3beta, 17beta-diol with estradiol and dihydrotestosterone receptors in human myometrial and mammary cancer tissue.
    Poortman J; Prenen JA; Schwarz F; Thijssen JH
    J Clin Endocrinol Metab; 1975 Mar; 40(3):373-9. PubMed ID: 163841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of the progesterone antagonist 17 beta-hydroxy-11 beta-(4-dimethylaminophenyl)-17 alpha-(1-propynyl) estra-4,9-dien-3-one in the rabbit.
    Wang G; Aedo AR; Cekan SZ
    Arzneimittelforschung; 1986 Jun; 36(6):936-8. PubMed ID: 3741527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation.
    Bertagna X; Escourolle H; Pinquier JL; Coste J; Raux-Demay MC; Perles P; Silvestre L; Luton JP; Strauch G
    J Clin Endocrinol Metab; 1994 Feb; 78(2):375-80. PubMed ID: 8106625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RU 486 prevents the acute effects of cortisol on glucose and leucine metabolism.
    Garrel DR; Moussali R; De Oliveira A; Lesiège D; Larivière F
    J Clin Endocrinol Metab; 1995 Feb; 80(2):379-85. PubMed ID: 7888013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A direct immunoradiometric assay for human plasma prorenin: concentrations in cycling women and in women taking oral contraceptives.
    Schumacher M; Nanninga A; Delfs T; Mukhopadhyay AK; Leidenberger FA
    J Clin Endocrinol Metab; 1992 Aug; 75(2):617-23. PubMed ID: 1639960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitation of RU 486 in human plasma by HPLC and RIA after column chromatography.
    Heikinheimo O; Tevilin M; Shoupe D; Croxatto H; Lähteenmäki P
    Contraception; 1986 Dec; 34(6):613-24. PubMed ID: 3829676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex steroid modulation of neurohypophysial hormone receptors in human nonpregnant myometrium.
    Maggi M; Magini A; Fiscella A; Giannini S; Fantoni G; Toffoletti F; Massi G; Serio M
    J Clin Endocrinol Metab; 1992 Feb; 74(2):385-92. PubMed ID: 1309835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation.
    Croxatto HB; Salvatierra AM; Romero C; Spitz IM
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1272-7. PubMed ID: 3119656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiovulatory actions of RU 486: the pituitary is not the primary site of action in vivo.
    Heikinheimo O; Gordon K; Lähteenmäki P; Williams RF; Hodgen GD
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1859-68. PubMed ID: 7775633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Radioreceptor assay for determination of the anti-progestogen, RU-486 and its active metabolites in the blood].
    Földesi I; Falkay G; Kovács L
    Acta Pharm Hung; 1992 Nov; 62(6):271-7. PubMed ID: 1488912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relationship of changes in serum estradiol and progesterone during the menstrual cycle to the thyrotropin and prolactin responses to thyrotropin-releasing hormone.
    Sawin CT; Hershman JM; Boyd AE; Longcope C; Bacharach P
    J Clin Endocrinol Metab; 1978 Dec; 47(6):1296-302. PubMed ID: 122427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RU 486: an overview of mifepristone and its potential applications.
    Contracept Rep; 1993 May; 4(2):7-9. PubMed ID: 12286473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects.
    Laue L; Lotze MT; Chrousos GP; Barnes K; Loriaux DL; Fleisher TA
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1474-80. PubMed ID: 2172280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception.
    Glasier A; Thong KJ; Dewar M; Mackie M; Baird DT
    N Engl J Med; 1992 Oct; 327(15):1041-4. PubMed ID: 1522839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The role of the progesterone antagonist, RU 486 (mifepristone), in preoperative cervical dilatation during the luteal phase. A randomized double-blind study].
    Fernandez H; Durlot F; Dubois C; Ulmann A; Frydman R
    Contracept Fertil Sex (Paris); 1990 Jan; 18(1):41-3. PubMed ID: 12283016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estrogen receptors in normal human myometrium and leiomyoma.
    Pollow K; Schmidt-gollwitzer M; Boquoi E; Pollow B
    J Mol Med; 1977 Jan; 2(1):61-8. PubMed ID: 12308704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
    Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
    J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The synergistic abortive effect of anti-progestogen RU 38486 and aromatase inhibitors for pregnant rat].
    Sasaki J; Yamamoto T; Okada H
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb; 41(2):179-84. PubMed ID: 2723486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RU 486 research forges on, despite political hurdles.
    Watanabe ME
    Scientist; 1994 Jan; 8(2):14-5. PubMed ID: 12288152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.